Skip Navigation

CAR T-Cell Therapy for Leukemia

  • Hematologic Oncology nurse Ilene Galinsky, BSN, NP, and physician Daniel DeAngelo, MD, PhD


    Leukemia nurse practitioner Ilene Galinsky and physician Daniel DeAngelo

  • CAR T-cell therapy is a promising treatment for patients with many types of blood cancer, including leukemia. It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer.

    Learn more about CAR T-cell therapy.

    Kymriah (also referred to as tisagenlecleucel), the first CAR T-cell therapy approved by the FDA, is approved for patients up to age 25 with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Kymriah marked a significant treatment advance for patients whose disease has become resistant to most standard chemotherapy agents. The clinical trials of Kymriah that led to FDA approval showed that 83 percent of patients achieved complete remission (i.e., no sign of cancer) within 3 months of treatment.

    Dana-Farber/Brigham and Women's Cancer Center is a certified treatment center for Kymriah for young adults ages 18 to 25.

    Dana-Farber/Boston Children's Cancer and Blood Disorders Center is also a certified treatment center for Kymriah for patients up to age 25.

    Patients are evaluated carefully to determine if this therapy is appropriate for them, and are cared for by a team experienced in CAR T-cell therapy.

    In addition to the FDA-approved therapy, DF/BWCC also offers clinical trials evaluating CAR T-cell therapy for other types of leukemia, as well as other blood cancers.

  • Dana-Farber/ Brigham and Women's Cancer Center
  • Contact Information for CAR T-Cell Therapy

    For more information about CAR T-cell therapy, please call 877-801-CART (2278) or email cartinquiries@dfci.harvard.edu.

  • Pediatric CAR T-Cell Therapy

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).